Albumin Mass Balance in Liver Transplantation

Sponsor
Ake Norberg (Other)
Overall Status
Recruiting
CT.gov ID
NCT03441035
Collaborator
(none)
200
1
39.1
5.1

Study Details

Study Description

Brief Summary

This clinical observational cohort study assess the loss of albumin from blood circulation during and after liver transplantation by mass balance of albumin. The overall assumption of this method is that if albumin is more diluted than hemoglobin, it must have left the plasma, presumably into the interstitial space. Predictors of albumin leakage will be assessed, including biomarkers of inflammation and of endothelial damage and dysfunction. The sub cohorts children and patients with complications, defined as prolonged postoperative treatment in the intensive care unit, respectively, will be focused in separate publications.

Condition or Disease Intervention/Treatment Phase
  • Other: General anesthesia and surgery (liver transplantation)

Detailed Description

Background Capillary leakage has been recognized to be associated with surgery and inflammation [Fleck 1985]. In liver transplantation considerable amounts of exogenous albumin is administered to support circulatory stability and a post operative plasma albumin concentration of 25 g/L to facilitate interpretation of immuno suppressive drug concentrations. However, the long term effects of exogenous albumin is not well characterized in the literature, and extravasation might promote edema formation and impair wound healing. In previous studies we have demonstrated the ability of the albumin mass balance method to identify leakage of albumin in major abdominal surgery [Norberg 2016].

In a pilot study in patients undergoing liver transplantation (n=11) we found a net leakage of albumin from plasma of 37 ± 17 g at end of surgery and 48 ± 33 g at postoperative day 3.

The primary aim of the new study is to find if this net leakage is still there at postoperative day 7. We are also looking into predictors of positive albumin shift from plasma including markers of inflammation and endothelial injury or dysfunction. Focus will also be put on the subgroup of children during and after liver transplantation. Finally a subgroup of patients in need of prolonged ICU stay after liver transplantation will be investigated to see the prolonged effects of our present routines, and these patients ability to synthetize albumin.

All patients undergoing liver transplantation at Karolinska University Hospital are eligible.

Recruitment will be made in advance as soon as patients are put on the transplant waiting list. In adults, at the day of surgery, blood samples will be taken repeatedly for estimation of plasma albumin. In all patients we will keep track of any gains or losses of albumin or hemoglobin in suction bottles, drains, exogenous blood products, exogenous albumin etc. This sampling will proceed during the study period that will end at hospital discharge or not later than post-operative day 21. Adult patients that are still in the ICU on postoperative day 3 will be subjected to a measurement of albumin synthesis rate by the flooding method [Ballmer 1993]. All subjects, even children, will have blood sampled for ELISAs of markers of inflammation and endothelial injury or dysfunction.

Total study specific blood sampling will be limited to 100 mL in adults and 6 mL in children.

Study Design

Study Type:
Observational
Anticipated Enrollment :
200 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Albumin Mass Balance in Liver Transplantation, an Open Prospective Cohort Study
Actual Study Start Date :
Mar 27, 2018
Anticipated Primary Completion Date :
Feb 28, 2021
Anticipated Study Completion Date :
Jun 30, 2021

Arms and Interventions

Arm Intervention/Treatment
Adults, uncomplicated

Adults undergoing liver transplantation. Mass balance of albumin will be undertaken by sampling of albumin in plasma and in all fluids that is infused or lost from the body to keep track of albumin and hemoglobin changes until postoperative day 7. B-Hb is taken routinely and not study specific samples. Plasma for ELISAs is taken at 2-3 time points.

Other: General anesthesia and surgery (liver transplantation)
The effects of general anesthesia and surgery under the hospital routine of albumin administration during and after liver transplantation is studied with the mass balance of albumin method.

Adults, complicated

Adults undergoing liver transplantation. Mass balance of albumin will be undertaken by sampling of albumin in plasma and in all fluids that is infused or lost from the body to keep track of albumin and hemoglobin changes until hospital discharge or postoperative day 21. B-Hb is taken routinely and not study specific samples. Plasma for ELISAs is taken at 2-3 time points. A infusion of deuterium labeled phenylalanine will be given in the ICU at 1-3 occasions to determine the synthesis rate of albumin.

Other: General anesthesia and surgery (liver transplantation)
The effects of general anesthesia and surgery under the hospital routine of albumin administration during and after liver transplantation is studied with the mass balance of albumin method.

Children

Children undergoing liver transplantation. Mass balance of albumin will be undertaken by sampling of albumin in in all fluids that is infused or lost from the body to keep track of albumin and hemoglobin changes until postoperative day 7. P-albumin and B-Hb is only taken routinely and not study specific samples. Plasma for ELISAs is taken at 2-3 time points.

Other: General anesthesia and surgery (liver transplantation)
The effects of general anesthesia and surgery under the hospital routine of albumin administration during and after liver transplantation is studied with the mass balance of albumin method.

Outcome Measures

Primary Outcome Measures

  1. Cumulative perioperative shift of albumin [Post-operative day 7 after liver transplantation]

    By mass balance of albumin (i.e keeping track of all gains and losses of albumin and compare these to hemoglobin) it is possible to estimate the loss of albumin from plasma that is not explained by losses in bleeding or drains.

Secondary Outcome Measures

  1. Predictors of cumulative perioperative shift of albumin [from pre-operative risk assessment until post-operative day 7]

    anthropometric and laboratory values including markers of inflammation and endothelial injury or dysfunction will be analyzed by regression analysis to cumulative perioperative shift of albumin

  2. Predictors of prolonged need for ICU stay [from pre-operative risk assessment until post-operative day 21]

    anthropometric and laboratory values including markers of inflammation and endothelial injury or dysfunction will be analyzed by regression analysis to Patients in need or not in need of prolonged ICU treatment

  3. Albumin synthesis rate [postoperative days 3-21 after liver transplantation]

    By deuterium labeled phenylalanine it is possible to assess albumin synthesis rate by the "flooding technique"

  4. Cumulative perioperative shift of albumin in children [during and after liver transplantation until postoperative day 21]

    By mass balance of albumin (i.e keeping track of all gains and losses of albumin and compare these to hemoglobin) it is possible to estimate the loss of albumin from plasma that is not explained by losses in bleeding or drains.

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:

All patients undergoing liver transplantation are eligible

Exclusion Criteria:

No consent Unability to understand the study information (language or consciousness)

Contacts and Locations

Locations

Site City State Country Postal Code
1 Karolinska University Hospital, Huddinge Huddinge Sweden 14186

Sponsors and Collaborators

  • Ake Norberg

Investigators

  • Principal Investigator: Åke Norberg, Ass Prof, Perioperative Medicine and Intensive Care, Karolinska University Hospital Huddinge

Study Documents (Full-Text)

More Information

Publications

Responsible Party:
Ake Norberg, Associate professor, Senior Consultant, Karolinska Institutet
ClinicalTrials.gov Identifier:
NCT03441035
Other Study ID Numbers:
  • K2017-4774
  • 4-3344/2017
First Posted:
Feb 22, 2018
Last Update Posted:
Sep 3, 2020
Last Verified:
Sep 1, 2020
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 3, 2020